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Table 1:   Sample characteristics
Subthreshold depression is one of the most frequent mental comorbidities 
in people with diabetes and is associated with a poorer long-term prog-
nosis. Since specific intervention concepts are missing a new self-manage-
ment oriented group programme (DIAMOS) was developed for this patient 
group and evaluated in a randomised trial.
B A C K G R O U N D & A I M S
C O N C L U S I O N
R E S U L T S
M E T H O D SM A T E R I A L S & M E T H O D S
DIAMOS comprises cognitive-behavioural interventions aiming at the 
reduction of diabetes distress. The active control group (CG) received 
diabetes education. Patients completed the following psychometric ques-
tionnaires at baseline and 12-month follow-up: Center of Epidemiologi-
cal Studies Depression Scale (CES-D), Patient Health Questionnaire (PHQ 
9), Problem Areas in Diabetes Scale (PAID), Diabetes Distress Scale (DDS), 
WHO-Five Well-being Index (WHO-5), Summary of Diabetes Self-care Ac-
tivities Measure (SDSCA), Acceptance and Action Diabetes Questionnaire 
(AADQ), and Diabetes Treatment Satisfaction Questionnaire (DTSQ). The 
primary outcome was the reduction of depressive symptoms (CES-D, PHQ-
9). Secondary outcomes were changes in diabetes distress (PAID, DDS), well-
being (WHO-5), self-care behaviour (SDSCA), diabetes acceptance (AADQ), 
treatment satisfaction (DTSQ), HbA
1c 
and inflammatory markers. 214 
patients were randomised; the study flow is displayed in figure 1.
• Baseline characteristics (age 43.3 ±13.3 yrs., female gender 56.5%, 
diabetes duration 14.2 ±10.5 yrs., type 2 diabetes 34.1%, BMI 28.7 
±71 kg/m²) were comparable in both groups except for diabetes 
types, BMI and macrovascular complications (see table 1).
• At 12-month follow-up there was a significantly greater reduction of 
depressive symptoms according to the CES-D and PHQ-9 scores in 
DIAMOS than in the CG (Δ -3.7 respectively Δ -1.5, all p < .05) (see 
figures 2 and 3). Per-protocol as well as intention-to-treat analyses 
revealed significant superiority of DIAMOS in reducing depressive 
symptoms (see figure 4).
• Moreover, the risk of incident major depression (assessed by the 
PHQ-9) in DIAMOS was significantly reduced (OR 0.63, 95%-CI 0.42 
to 0.96, p = .028) (see figure 5).
• Additionally, diabetes distress as measured by the PAID and DDS was 
significantly more strongly reduced in DIAMOS (Δ -8.3 respectively Δ 
-0.22, all p < .05) (see figures 6 and 7).
• HbA
1c
 was significantly improved in DIAMOS and the CG without a 
significant difference between the groups (see figure 8).
DIAMOS is effective in lowering depressive symptoms and diabetes-rela-
ted distress in people with diabetes patients and subthreshold depression. 
Moreover, DIAMOS has a preventive effect regarding the incidence of ma-
jor depression.
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Figure 1:  Study flow chart
• No significant between-group differences were observed regarding 
well-being, self-care behaviour, diabetes acceptance and treatment 
satisfaction (data not shown).
• Regarding inflammatory markers (IL-1RA, IL-6 and adiponectin) no 
significant effects were observed (data not shown).
Fig. 4:  Reduction of depressive symptoms (CES-D) in per-protocol and intention-to-treat analyses 
(adjusted mean differences and 95% confidence intervals)
Fig. 5: Reduction of major depression incidence 
(PHQ-9)
Fig. 2: Reduction of depressive symptoms (CES-D) Fig. 3: Reduction of depressive symptoms (PHQ-9)
1 mean ± standard deviation; ² mean adjusted between group baseline-endpoint-change adjusted for 
BMI, diabetes type, and baseline values 
Fig. 7: Reduction of diabetes-related distress (DDS) Fig. 8:  Improvement of HbA
1c
Fig. 6: Reduction of diabetes-related distress (PAID)
